


IMMUNOASSAYS AND SERVICES BIOGENIC AMINES & NEUROSCIENCE | ENDOCRINOLOGY | FOOD SAFETY

LABOR DIAGNOSTIKA NORD GmbH & Co.KG | Am Eichenhain 1 | 48531 Nordhorn | Germany | Tel. +49 5921 8197-0 | Fax +49 5921 8197-222 | info@ldn.de | www.ldn.de

Instructions for use **DHEA-S ELISA**







DHEA-S ELISA

INTENDED USE

For the direct quantitative determination of DHEA-S by enzyme immunoassay in human serum. For *in vitro* diagnostic use only.

PRINCIPLE OF THE TEST

The principle of the following enzyme immunoassay test follows the typical competitive binding scenario. Competition occurs between an unlabeled antigen (present in standards, controls and patient samples) and an enzyme-labelled antigen (conjugate) for a limited number of antibody binding sites on the microwell plate. The washing and decanting procedures remove unbound materials. After the washing step, the enzyme substrate is added. The enzymatic reaction is terminated by addition of the stopping solution. The absorbance is measured on a microtiter plate reader. The intensity of the colour formed is inversely proportional to the concentration of DHEAS in the sample. A set of standards is used to plot a standard curve from which the amount of DHEAS in patient samples and controls can be directly read.

CLINICAL APPLICATIONS

Dehydroepiandrosterone sulfate (DHEAS) is produced by the adrenals and gonads. As a result, the determination of the level of DHEA-S in serum is important in the evaluation of the functional state of these glands. DHEAS is a precursor of testosterone and estrone. Besides the adrenals in females, the ovaries have been shown to be an important source of DHEAS. It has been reported that there is a fluctuation day by day of DHEAS in women during the ovulatory cycle.

The principle production of testosterone in females is from conversion of other related androgens, especially

DHEAS. An abnormal testosterone level in women should be accompanied by the estimation of serum DHEAS. The use of serum testosterone determination in conjunction with Elisa of DHEAS can be used to determine if the source of excess androgen production is ovarian or adrenal.

PROCEDURAL CAUTIONS AND WARNINGS

- 1. Users should have a thorough understanding of this protocol for the successful use of this kit. Reliable performance will only be attained by strict and careful adherence to the instructions provided.
- 2. Control materials or serum pools should be included in every run at a high and low level for assessing the reliability of results.
- 3. When the use of water is specified for dilution or reconstitution, use deionized or distilled water.
- 4. In order to reduce exposure to potentially harmful substances, gloves should be worn when handling kit reagents and human specimens.
- 5. All kit reagents and specimens should be brought to room temperature and mixed gently but thoroughly before use. Avoid repeated freezing and thawing of reagents and specimens.
- 6. A calibrator curve must be established for every run.
- 7. The controls should be included in every run and fall within established confidence limits.
- 8. Improper procedural techniques, imprecise pipetting, incomplete washing as well as improper reagent storage may be indicated when assay values for the controls do not reflect established ranges.
- 9. When reading the microplate, the presence of bubbles in the microwells will affect the optical densities (ODs). Carefully remove any bubbles before performing the reading step.
- 10. The substrate solution (TMB) is sensitive to light and should remain colourless if properly stored. Instability or contamination may be indicated by the development of a blue colour, in which case it should not be used.
- 11. When dispensing the substrate and stopping solution, do not use pipettes in which these liquids will come into contact with any metal parts.
- 12. To prevent contamination of reagents, use a new disposable pipette tip for dispensing each reagent, sample, standard and control.
- 13. Do not mix various lot numbers of kit components within a test and do not use any component beyond the expiration date printed on the label.
- 14. Kit reagents must be regarded as hazardous waste and disposed of according to national regulations.

LIMITATIONS

- 1. All the reagents within the kit are calibrated for the direct determination of DHEAS in human serum. The kit is not calibrated for the determination of DHEAS in saliva, plasma or other specimens of human or animal origin.
- 2. Do not use grossly hemolyzed, grossly lipemic, icteric or improperly stored serum.
- 3. Any samples or control sera containing azide or thimerosal are not compatible with this kit, as they may lead to false results.
- 4. Only calibrator A may be used to dilute any high serum samples. The use of any other reagent may lead to false results.
- 5. The results obtained with this kit should never be used as the sole basis for a clinical diagnosis. For example, the occurrence of heterophilic antibodies in patients regularly exposed to animals or animal products has the potential of causing interferences in immunological tests. Consequently, the clinical diagnosis should include all aspects of a patient's background including the frequency of exposure to animals/products if false results are suspected.

SAFETY CAUTIONS AND WARNINGS POTENTIAL BIOHAZARDOUS MATERIAL

Human serum that may be used in the preparation of the standards and controls has been tested and found to be non-reactive for Hepatitis B surface antigen and has also been tested for the presence of antibodies to HCV and Human Immunodeficiency Virus (HIV) and found to be negative. However no test method can offer complete assurance that HIV, HCV and Hepatitis B virus or any infectious agents are absent. The reagents should be considered a potential biohazard and handled with the same precautions as applied to any blood specimen.

CHEMICAL HAZARDS

Avoid contact with reagents containing TMB, hydrogen peroxide and sulfuric acid. If contacted with any of these reagents, wash with plenty of water. TMB is a suspected carcinogen.

SPECIMEN COLLECTION AND STORAGE

Approximately 0.1 ml of serum is required per duplicate determination. Collect 4-5 ml of blood into an appropriately labelled tube and allow it to clot. Centrifuge and carefully remove the serum layer. Store at 4° C for up to 24 hours or at -10° C or lower if the analyses are to be done at a later date. Consider all human specimens as possible biohazardous materials and take appropriate precautions when handling.

SPECIMEN PRETREATMENT

This assay is a direct system; no specimen pretreatment is necessary.

REAGENTS AND EQUIPMENT NEEDED BUT NOT PROVIDED

- Precision pipettes to dispense 25, 50, 100, 150 and 300 μl
- Disposable pipette tips
- Distilled or deionized water
- Plate shaker
- Microwell plate reader with a filter set at 450nm and an upper OD limit of 3.0 or greater* (see assay procedure step 10).

REAGENTS PROVIDED

| AA E-0030 | WASH-CONC 10x Wash Buffer Concentrate – X10 | | | | |
|--------------|--|--|--|--|--|
| Contents: | One bottle containing buffer with a non-ionic detergent and a non-mercury preservative. | | | | |
| Volume: | 50 ml/bottle | | | | |
| Storage: | Refrigerate at 2-8°C | | | | |
| Stability: | 12 months or as indicated on label. | | | | |
| Preparation: | Dilute 1:10 in distilled or deionized water before use. If the whole plate is to be used dilute 50 ml of the wash buffer concentrate in 450 ml of water. | | | | |
| AA E-0055 | SUBSTRATE TMB Substrate - Ready To Use. | | | | |
| Contents: | One bottle containing tetramethylbenzidine and hydrogen peroxide in a non-DMF or DMSO containing buffer. | | | | |
| Volume: | 16 ml/bottle | | | | |
| Storage: | Refrigerate at 2-8°C | | | | |
| Stability: | 12 months or as indicated on label. | | | | |
| AA E-0080 | STOP-SOLN Stopping Solution - Ready To Use. | | | | |
| Contents: | One vial containing 1M sulfuric acid. | | | | |
| Volume: | 6 ml/vial | | | | |
| Storage: | Refrigerate at 2-8°C | | | | |

Stability: 12 months or as indicated on label.

Calibrators and Controls- Ready To Use.

Listed below are approximate concentrations, please refer to vial labels for exact concentrations:

| Cat. no. | Symbol | Calibrator | Concentration | Volume/Vial | |
|--------------|---|---|---|-----------------------|--|
| AA E-1101 | STANDARD A | Calibrator A | 0 µg/ml | 2.0 ml | |
| AA E-1102 | STANDARD B | Calibrator B | 0.005 µg/ml | 0.5 ml | |
| AA E-1103 | | Calibrator C | 0.02 µg/ml | 0.5 ml | |
| AA E-1104 | | Calibrator D | 0.1 µg/ml | 0.5 ml | |
| AA E-1105 | | Calibrator E | 0.5 μg/ml | 0.5 ml | |
| AA E-1106 | | Calibrator F | 2.5 μg/ml | 0.5 ml | |
| AA E-1107 | STANDARD G | Calibrator G | 10 µg/ml | 0.5 ml | |
| AA E-1151 | | Control 1 | Refer to vial labels for expected | 0.5 ml | |
| AA E-1152 | CONTROL 2 | Control 2 | value and acceptable range! | 0.5 ml | |
| Contents: | DHEAS in a p | protein-based buff d quantity of DHE | fer with a non-mercury preservative EAS. | . Prepared by spiking | |
| Storage: | Refrigerate a | t 2-8°C | | | |
| Stability: | | | or as indicated on label. Once opene ed and stored frozen. Avoid multipl | | |
| AA E-1113 | ASSAY-BUFF | - | - Ready To Use. | | |
| Contents: | One vial containing a protein-based buffer with a non-mercury preservative. | | | | |
| /olume: | 30 ml/vial | | | | |
| Storage: | - | Refrigerate at 2-8°C | | | |
| Stability: | 12 months o | r as indicated on I | label. | | |
| A E-1131 | Ш 96 | Rabbit Anti-D - Ready To Use | DHEAS Antibody Coated Microwe | ll Plate-Break Apart | |
| Contents: | One 96 well (12x8) polyclonal antibody-coated microwell plate in a resealable pouch with desiccant. | | | | |
| Storage: | Refrigerate a | t 2-8°C | | | |
| Stability: | 12 months o | r as indicated on I | label. | | |
| AA E-1140 | CONJUGATE-CONC 50 | DHEAS-Horse | eradish Peroxidase (HRP) Conjug | ate Concentrate – X | |
| Contents: | DHEAS-HRP conjugate in a protein-based buffer with a non-mercury preservative. | | | | |
| /olume: | 0.8 ml/vial | | | | |
| Storage: | Refrigerate at 2-8°C | | | | |
| Stability: | 12 months or as indicated on label. | | | | |
| Preparation: | | | fore use (eg. 40 µl of HRP in 2 ml of e 0.5 ml of HRP in 25 ml of assay bu | | |

ASSAY PROCEDURE

Specimen Pretreatment: None.

All reagents must reach room temperature before use. Calibrators, controls and specimen samples should be assayed in duplicate. Once the procedure has been started, all steps should be completed without interruption.

| 1. | Prepare working solutions of the DHEAS-HRP conjugate and wash buffer. |
|-----|--|
| 2. | Remove the required number of microwell strips. Reseal the bag and return any unused strips to the refrigerator. |
| 3. | Pipette 25 μl of each calibrator, control and specimen sample into correspondingly labelled wells in duplicate. |
| 4. | Pipette 200 μl of the conjugate working solution into each well. |
| | (We recommend using a multichannel pipette). |
| 5. | Incubate on a plate shaker (approximately 200 rpm) for 45 minutes at room temperature. |
| 6. | Wash the wells 3 times with 300 µl of diluted wash buffer per well and tap the plate firmly against absorbent paper to ensure that it is dry (<i>The use of a washer is recommended</i>). |
| 7. | Pipette 150 µl of TMB substrate into each well at timed intervals. |
| 8. | Incubate the plate on a plate shaker for 15-20 minutes at room temperature. |
| | (or until Calibrator A attains dark blue colour for desired OD). |
| 9. | Pipette 50 µl of stopping solution into each well at the same timed intervals as in step 7. |
| 10. | Read the plate on a microwell plate reader at 450 nm within 20 minutes after addition of the stopping solution. |
| | If the OD exceeds the upper limit of detection or if a 450nm filter is unavailable, a 405 or 415nm filter may be substituted. The optical densities will be lower, however, this will not affect the results of patient/control samples. |
| | |

CALCULATIONS


- 1. Calculate the mean optical density of each calibrator duplicate.
- 2. Draw a calibrator curve on semi-log paper with the mean optical densities on the Y-axis and the calibrator concentrations on the X-axis. If immunoassay software is being used, a 4-parameter or 5-parameter curve is recommended.
- 3. Calculate the mean optical density of each unknown duplicate.
- 4. Read the values of the unknowns directly off the calibrator curve.
- 5. If a sample reads more than 10 μ g/ml then dilute it with calibrator A at a dilution of no more than 1:8. The result obtained should be multiplied by the dilution factor.

| Calibrator | OD : | OD 2 | Mean OD | Value (µg/ml) |
|------------|-------|-------|---------|------------------|
| A | 2.106 | 2.060 | 2.083 | 0 |
| В | 1.910 | 1.863 | 1.887 | 0.005 |
| С | 1.636 | 1.769 | 1.703 | 0.02 |
| D | 1.398 | 1.382 | 1.390 | 0.1 |
| E | 0.966 | 0.938 | 0.952 | 0.5 |
| F | 0.496 | 0.479 | 0.488 | 2.5 |
| G | 0.250 | 0.252 | 0.251 | 10 |
| Unknown | 0.690 | 0.688 | 0.689 | 1.20 |

TYPICAL TABULATED DATA

TYPICAL CALIBRATOR CURVE

Sample curve only. **Do not** use to calculate results.



PERFORMANCE CHARACTERISTICS

SENSITIVITY

The lower detection limit is calculated from the standard curve by determining the resulting concentration of the mean OD of Calibrator A (based on 10 replicate analyses) minus 2 SD. Therefore, the sensitivity of the Direct DHEAS ELISA kit is **0.005 \mug/ml**.

SPECIFICITY (CROSS REACTIVITY)

The following compounds were tested for cross-reactivity with the Direct DHEAS ELISA kit with DHEAS cross-reacting at 100%.

| Steroid | %Cross Reactivity |
|-----------------|----------------------|
| DHEAS | 100 |
| Androsterone | 16.0 |
| Androstenedione | 1.7 |
| Testosterone | 0.9 |
| Progesterone | 0.6 |
| DHT | 0.6 |
| Cortisol | 0.5 |

The following steroids were tested but cross-reacted at less than 0.001%: 17β-Estradiol, Estrone, Estrone-Sulfate and Pregnenolone.

INTRA-ASSAY PRECISION

Three samples were assayed ten times each on the same calibrator curve. The results (in μ g/ml) are tabulated below:

| Sample | Mean | SD | CV% |
|--------|------|------|------|
| 1 0.24 | | 0.02 | 7.5 |
| 2 2.02 | | 0.18 | 8.9 |
| 3 9.54 | | 0.11 | 11.5 |

INTER-ASSAY PRECISION

Three samples were assayed ten times over a period of four weeks. The results (in µg/ml) are tabulated below:

| Sample | Mean | SD | CV% |
|--------|------|------|------|
| 1 | 0.13 | 0.02 | 15.3 |
| 2 | 1.11 | 0.09 | 8.1 |
| 3 | 6.38 | 0.27 | 4.2 |

RECOVERY

Spiked samples were prepared by adding defined amounts of DHEAS to three patient serum samples. The results

(in μ g/ml) are tabulated below:

| Sample | Obs.Result | Exp.Result | Recovery% |
|------------|------------|------------|-----------|
| 1 Unspiked | 0.67 | - | - |
| +0.1 | 0.84 | 0.77 | 109.1 |
| +1.0 | 1.97 | 1.67 | 117.9 |
| +5.0 | 5.80 | 5.67 | 102.3 |
| 2 Unspiked | 1.06 | - | - |
| +0.1 | 1.40 | 1.16 | 120.7 |
| +1.0 | 1.82 | 2.06 | 88.3 |
| +5.0 | 5.26 | 6.06 | 86.8 |
| 3 Unspiked | 1.73 | - | - |
| +0.1 | 1.90 | 1.83 | 103.8 |
| +1.0 | 2.21 | 2.73 | 80.9 |
| +5.0 | 5.79 | 6.73 | 86.0 |

LINEARITY

Three patient serum samples were diluted with calibrator A. The results (in µg/ml) are tabulated below:

| Sample Obs.Result | | Exp.Result | Recovery% |
|-------------------|------|------------|-----------|
| 1 | 2.84 | - | - |
| 1:2 | 1.48 | 1.42 | 104.2 |
| 1:4 | 0.81 | 0.71 | 87.8 |
| 1:8 | 0.46 | 0.36 | 104.2 |
| 2 | 6.32 | - | - |
| 1:2 | 3.17 | 3.16 | 100.3 |
| 1:4 | 1.63 | 1.58 | 103.2 |
| 1:8 | 0.78 | 0.79 | 98.7 |
| 3 | 7.12 | - | - |
| 1:2 | 3.09 | 3.56 | 86.8 |
| 1:4 | 1.78 | 1.78 | 86.5 |
| 1:8 | 0.80 | 0.89 | 89.9 |

EXPECTED NORMAL VALUES

As for all clinical assays each laboratory should collect data and establish their own range of expected normal values.

| Group | Range (µg/ml) |
|----------------|---------------|
| Males | 0.39-4.63 |
| Females | 0.46-2.75 |
| Postmenopausal | 0.48-2.08 |
| Females | |

REFERENCES

- Chasalow, F.I., Blethen, S.L. and Bradlow, H.L. Dehydroepiandrosterone sulfate (DHEAS) and DHEAS-like compounds in fibrocystic disease of the breast. Steroids 52/3: 205-215, 1988.
- Chasalow, F.I., et al., Serum levels of dehydroepiandrosterone sulfate as determined by commercial kits and reagents. Steroids 54/4: 373-381, 1989.
- de Peretti, E. and Forest, M.G. Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: Evidence for testicular production. J. Clin. Endocr. 47: 572-577, 1978.
- Holtzclaw, W.D. and Gordon, G.B. Measurement of serum levels of dehydroepiandrosterone sulfate: A comparison of Elisa and enzymatic analysis. Steroids 54/4: 355-371, 1989.
- Koritnik, D.R., et al., An Elisa for DHEAS in the ciruclation of rhesus monkeys. Steroids 42/6: 653-664, 1984.
- Orentreich, N., Brind, et al., Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocr. 59: 551-555, 1984.
- Smith, M.R., et al., An Elisa for the estimation of serum dehydroepiandrosterone sulfate in normal and pathological sera. Clin. Chim. Acta 65: 5-13, 1975.
- Check, J.H., et al, Falsely elevated steroidal assay levels related to heterophile antibodies against various animal species. Gynecol Obstet Invest 40:139-140, 1995.

Symbols:

| Symbols. | | | | | |
|-----------|------------------------------|------|---------------------|-------|--|
| +2 °C | Storage temperature | ~~~ | Manufacturer | Σ | Contains sufficient for <n> tests</n> |
| 2 | Expiry date | LOT | Batch code | I V D | For in-vitro diagnostic use only! |
| i | Consult instructions for use | CONT | Content | CE | CE labelled |
| Λ | Caution | REF | Catalogue number | RUO | For research use only! |